

# Oryan Henig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7554200/publications.pdf>

Version: 2024-02-01

20  
papers

554  
citations

1039880

9  
h-index

887953

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of antibiotics and factors associated with treatment failure among 152,245 patients with pneumonia treated in the community – a retrospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 99-108.	1.3	0
2	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 341.	3.8	76
3	Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer. <i>Lancet Oncology</i> , The, 2022, 23, 193-195.	5.1	32
4	Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab656.	0.4	11
5	Rethinking the “Pan-Culture” Clinical Impact of Respiratory Culturing in Patients With Low Pretest Probability of Ventilator-Associated Pneumonia. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
6	Unraveling a Nosocomial Outbreak of COVID-19: The Role of Whole-Genome Sequence Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab120.	0.4	10
7	Deferring Amputation in Diabetic Foot Osteomyelitis: Doing More Harm Than Good?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab184.	0.4	5
8	Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2457.	3.8	190
9	Antibiotic Use during the COVID-19 Pandemic in a Tertiary Hospital with an Ongoing Antibiotic Stewardship Program. <i>Antibiotics</i> , 2021, 10, 1056.	1.5	14
10	An outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections among hospital personnel with high mRNA vaccine uptake. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-4.	1.0	2
11	The Performance of Sepsis-3 Criteria to Predict Mortality among patients with hematologic malignancy and post-transplant who have Suspected Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab529.	0.4	2
12	Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 71, 3033-3041.	2.9	10
13	The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa161.	0.4	23
14	The hypothetical impact of Accelerate Pheno <sup>®</sup> system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, i32-i39.	1.3	12
15	The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8
16	2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification. <i>Open Forum Infectious Diseases</i> , 2018, 5, S606-S606.	0.4	0
17	1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S453-S454.	0.4	0
18	Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy245.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i> . <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1461-1472.	1.1	67
20	Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant <i>A. baumannii</i> : A Review. <i>Infectious Diseases and Therapy</i> , 2017, 6, 199-211.	1.8	70